{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T21:58:43Z","timestamp":1766267923508,"version":"build-2065373602"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T00:00:00Z","timestamp":1746230400000},"content-version":"am","delay-in-days":275,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000097","name":"National Center for Research Resources","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["2240683"],"award-info":[{"award-number":["2240683"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gene"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.gene.2024.148500","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T21:19:59Z","timestamp":1713907199000},"page":"148500","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Development and characterization of a first-in-class adjustable-dose gene therapy system"],"prefix":"10.1016","volume":"919","author":[{"given":"Alex","family":"Goraltchouk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7169-4816","authenticated-orcid":false,"given":"Jared","family":"Lourie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2917-1471","authenticated-orcid":false,"given":"Judith M.","family":"Hollander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Grace Rosen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8193-5280","authenticated-orcid":false,"given":"Atsutaro A.","family":"Fujishiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Luppino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4164-7129","authenticated-orcid":false,"given":"Kai","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexey","family":"Seregin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.gene.2024.148500_b0005","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231710044","article-title":"Optimization of Signal Peptide via Site-Directed Mutagenesis for Enhanced Secretion of Heterologous Proteins in Lactococcus lactis","volume":"23","author":"Alias","year":"2022","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.gene.2024.148500_b0010","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.745325","article-title":"Activation of Toll-Like Receptors by Live Gram-Negative Bacterial Pathogens Reveals Mitigation of TLR4 Responses and Activation of TLR5 by Flagella","volume":"11","author":"Amemiya","year":"2021","journal-title":"Front Cell Infect Microbiol."},{"key":"10.1016\/j.gene.2024.148500_b0015","article-title":"Gene therapy clinical trials, where do we go?","volume":"153","author":"Arabi","year":"2022","journal-title":"An Overview. Biomed Pharmacother."},{"issue":"4","key":"10.1016\/j.gene.2024.148500_b0020","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1172\/JCI9459","article-title":"Gene silencing as a threat to the success of gene therapy","volume":"105","author":"Bestor","year":"2000","journal-title":"J Clin Invest."},{"issue":"12","key":"10.1016\/j.gene.2024.148500_b0025","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.cels.2022.11.005","article-title":"The sound of silence: Transgene silencing in mammalian cell engineering","volume":"13","author":"Cabrera","year":"2022","journal-title":"Cell Syst."},{"key":"10.1016\/j.gene.2024.148500_b0030","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.omtm.2023.05.013","article-title":"Strong ubiquitous micro-promoters for recombinant adeno-associated viral vectors","volume":"29","author":"Chai","year":"2023","journal-title":"Mol Ther Methods Clin Dev."},{"issue":"1","key":"10.1016\/j.gene.2024.148500_b0035","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1208\/s12248-021-00678-7","article-title":"The Perspective of DMPK on Recombinant Adeno-Associated Virus-Based Gene Therapy: Past Learning, Current Support, and Future Contribution","volume":"24","author":"Chen","year":"2022","journal-title":"AAPS J."},{"issue":"1","key":"10.1016\/j.gene.2024.148500_b0040","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1021\/acssynbio.2c00589","article-title":"Synthetic Biology Design as a Paradigm Shift toward Manufacturing Affordable Adeno-Associated Virus Gene Therapies","volume":"12","author":"Collins","year":"2023","journal-title":"ACS Synth Biol."},{"issue":"7","key":"10.1016\/j.gene.2024.148500_b0045","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.ymthe.2017.03.013","article-title":"Lipid Nanoparticle Systems for Enabling Gene Therapies","volume":"25","author":"Cullis","year":"2017","journal-title":"Mol Ther."},{"issue":"2","key":"10.1016\/j.gene.2024.148500_b0050","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1128\/IAI.74.2.940-946.2006","article-title":"Activation of toll-like receptor 9 by DNA from different bacterial species","volume":"74","author":"Dalpke","year":"2006","journal-title":"Infect Immun."},{"issue":"4","key":"10.1016\/j.gene.2024.148500_b0055","doi-asserted-by":"crossref","first-page":"e0203921","DOI":"10.1128\/jvi.02039-21","article-title":"Epigenetic Silencing of Recombinant Adeno-associated Virus Genomes by NP220 and the HUSH Complex","volume":"96","author":"Das","year":"2022","journal-title":"J Virol."},{"key":"10.1016\/j.gene.2024.148500_b0060","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.omtn.2021.03.008","article-title":"Functionalized lipid nanoparticles for subcutaneous administration of mRNA to achieve systemic exposures of a therapeutic protein","volume":"24","author":"Davies","year":"2021","journal-title":"Mol Ther Nucleic Acids."},{"issue":"17","key":"10.1016\/j.gene.2024.148500_b0065","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22179181","article-title":"Enzyme Therapy: Current Challenges and Future Perspectives","volume":"22","author":"de la Fuente","year":"2021","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.gene.2024.148500_b0070","article-title":"Immunotherapy and Gene Therapy: New Challenges in the Diagnosis and Management of Drug-Induced Liver Injury","volume":"12","author":"Delire","year":"2021","journal-title":"Front Pharmacol."},{"issue":"2","key":"10.1016\/j.gene.2024.148500_b0075","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2174\/1566523217666170510163038","article-title":"Lipid Nanoparticles as Potential Gene Therapeutic Delivery Systems for Oral Administration","volume":"17","author":"Dorraj","year":"2017","journal-title":"Curr Gene Ther."},{"issue":"17","key":"10.1016\/j.gene.2024.148500_b0080","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1016\/j.cell.2023.07.031","article-title":"Herpes simplex virus gene therapy for dystrophic epidermolysis bullosa (DEB)","volume":"186","author":"Epstein","year":"2023","journal-title":"Cell."},{"key":"10.1016\/j.gene.2024.148500_b0085","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.975803","article-title":"Immunogenicity and toxicity of AAV gene therapy","volume":"13","author":"Ertl","year":"2022","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.gene.2024.148500_b0090","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1021\/acs.accounts.1c00544","article-title":"Chemistry of Lipid Nanoparticles for RNA Delivery","volume":"55","author":"Eygeris","year":"2022","journal-title":"Acc Chem Res."},{"issue":"252\u20138","key":"10.1016\/j.gene.2024.148500_b0095","first-page":"e1","article-title":"Subacute Liver Failure Following Gene Replacement Therapy for Spinal Muscular Atrophy Type 1","volume":"225","author":"Feldman","year":"2020","journal-title":"J Pediatr."},{"issue":"9","key":"10.1016\/j.gene.2024.148500_b0100","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1089\/hum.2010.245","article-title":"Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors","volume":"22","author":"Gray","year":"2011","journal-title":"Hum Gene Ther."},{"key":"10.1016\/j.gene.2024.148500_b0105","doi-asserted-by":"crossref","first-page":"869","DOI":"10.3389\/fmicb.2016.00869","article-title":"Herpesvirus Late Gene Expression: A Viral-Specific Pre-initiation Complex Is Key","volume":"7","author":"Gruffat","year":"2016","journal-title":"Front Microbiol."},{"issue":"12","key":"10.1016\/j.gene.2024.148500_b0110","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s40262-018-0668-z","article-title":"Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist","volume":"57","author":"Hall","year":"2018","journal-title":"Clin Pharmacokinet."},{"issue":"12","key":"10.1016\/j.gene.2024.148500_b0115","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1016\/j.ymthe.2022.11.001","article-title":"Vector genome loss and epigenetic modifications mediate decline in transgene expression of AAV5 vectors produced in mammalian and insect cells","volume":"30","author":"Handyside","year":"2022","journal-title":"Mol Ther."},{"issue":"6813","key":"10.1016\/j.gene.2024.148500_b0120","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/35047123","article-title":"A Toll-like receptor recognizes bacterial DNA","volume":"408","author":"Hemmi","year":"2000","journal-title":"Nature."},{"issue":"12","key":"10.1016\/j.gene.2024.148500_b0125","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat Rev Mater."},{"issue":"14","key":"10.1016\/j.gene.2024.148500_b0130","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1089\/104303401750476230","article-title":"A high-efficiency synthetic promoter that drives transgene expression selectively in noradrenergic neurons","volume":"12","author":"Hwang","year":"2001","journal-title":"Hum Gene Ther."},{"issue":"11","key":"10.1016\/j.gene.2024.148500_b0135","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.it.2006.09.002","article-title":"Innate immune recognition of, and regulation by, DNA","volume":"27","author":"Ishii","year":"2006","journal-title":"Trends Immunol."},{"issue":"8","key":"10.1016\/j.gene.2024.148500_b0140","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1007\/s00125-005-1825-0","article-title":"Implantation of primary cultured adipocytes that secrete insulin modifies blood glucose levels in diabetic mice","volume":"48","author":"Ito","year":"2005","journal-title":"Diabetologia."},{"issue":"2","key":"10.1016\/j.gene.2024.148500_b0145","doi-asserted-by":"crossref","DOI":"10.3390\/cells10020240","article-title":"The Future of Regenerative Medicine: Cell Therapy Using Pluripotent Stem Cells and Acellular Therapies Based on Extracellular Vesicles","volume":"10","author":"Jarrige","year":"2021","journal-title":"Cells."},{"issue":"1","key":"10.1016\/j.gene.2024.148500_b0150","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1038\/s41467-019-11179-9","article-title":"Genome-wide systematic identification of methyltransferase recognition and modification patterns","volume":"10","author":"Jensen","year":"2019","journal-title":"Nat Commun."},{"issue":"12","key":"10.1016\/j.gene.2024.148500_b0155","doi-asserted-by":"crossref","first-page":"587","DOI":"10.5483\/BMBRep.2022.55.12.154","article-title":"Topological implications of DNA tumor viral episomes","volume":"55","author":"Kim","year":"2022","journal-title":"BMB Rep."},{"key":"10.1016\/j.gene.2024.148500_b0160","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.reth.2022.04.004","article-title":"Advanced Therapy medicinal products for autologous chondrocytes and comparison of regulatory systems in target countries","volume":"20","author":"Kim","year":"2022","journal-title":"Regen Ther."},{"key":"10.1016\/j.gene.2024.148500_b0165","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.omtn.2021.03.012","article-title":"DNA nuclear targeting sequences for enhanced non-viral gene transfer: An in vitro and in vivo study","volume":"24","author":"Le Guen","year":"2021","journal-title":"Mol Ther Nucleic Acids."},{"issue":"8","key":"10.1016\/j.gene.2024.148500_b0170","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/nm.3267","article-title":"Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies","volume":"19","author":"Lee","year":"2013","journal-title":"Nat Med."},{"key":"10.1016\/j.gene.2024.148500_b0175","doi-asserted-by":"crossref","first-page":"e00102","DOI":"10.7554\/eLife.00102","article-title":"Sequence specific detection of bacterial 23S ribosomal RNA by TLR13","volume":"1","author":"Li","year":"2012","journal-title":"Elife."},{"issue":"4","key":"10.1016\/j.gene.2024.148500_b0180","doi-asserted-by":"crossref","first-page":"205","DOI":"10.5732\/cjc.012.10065","article-title":"The propensity for tumorigenesis in human induced pluripotent stem cells is related with genomic instability","volume":"32","author":"Liang","year":"2013","journal-title":"Chin J Cancer."},{"issue":"4","key":"10.1016\/j.gene.2024.148500_b0185","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41577-021-00577-0","article-title":"Regulation of the nucleic acid-sensing Toll-like receptors","volume":"22","author":"Lind","year":"2022","journal-title":"Nat Rev Immunol."},{"issue":"10","key":"10.1016\/j.gene.2024.148500_b0190","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41573-023-00766-7","article-title":"AAV-based in vivo gene therapy for neurological disorders","volume":"22","author":"Ling","year":"2023","journal-title":"Nat Rev Drug Discov."},{"issue":"1","key":"10.1016\/j.gene.2024.148500_b0195","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s13238-017-0408-4","article-title":"Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins","volume":"9","author":"Liu","year":"2018","journal-title":"Protein Cell."},{"key":"10.1016\/j.gene.2024.148500_b0200","doi-asserted-by":"crossref","first-page":"1043789","DOI":"10.3389\/fendo.2022.1043789","article-title":"Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database","volume":"13","author":"Liu","year":"2022","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"9","key":"10.1016\/j.gene.2024.148500_b0205","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/mt.2008.156","article-title":"Advances in high-capacity extrachromosomal vector technology: episomal maintenance, vector delivery, and transgene expression","volume":"16","author":"Lufino","year":"2008","journal-title":"Mol Ther."},{"key":"10.1016\/j.gene.2024.148500_b0210","first-page":"229","article-title":"Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes","volume":"7","author":"Mann","year":"2014","journal-title":"Diabetes Metab Syndr Obes."},{"issue":"12","key":"10.1016\/j.gene.2024.148500_b0215","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1016\/S0022-2275(20)37472-1","article-title":"Effects of particle size and number on the plasma clearance of chylomicrons and remnants","volume":"37","author":"Martins","year":"1996","journal-title":"J Lipid Res."},{"issue":"8","key":"10.1016\/j.gene.2024.148500_b0220","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol."},{"issue":"12","key":"10.1016\/j.gene.2024.148500_b0225","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"Meier","year":"2012","journal-title":"Nat Rev Endocrinol."},{"issue":"2","key":"10.1016\/j.gene.2024.148500_b0230","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","article-title":"Current Clinical Applications of In Vivo Gene Therapy with AAVs","volume":"29","author":"Mendell","year":"2021","journal-title":"Mol Ther."},{"issue":"3","key":"10.1016\/j.gene.2024.148500_b0235","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/cpt.2972","article-title":"Model-Informed Approaches and Innovative Clinical Trial Design for Adeno-Associated Viral Vector-Based Gene Therapy Product Development: A White Paper","volume":"114","author":"Mitra","year":"2023","journal-title":"Clin Pharmacol Ther."},{"issue":"3","key":"10.1016\/j.gene.2024.148500_b0240","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s12325-022-02394-w","article-title":"GLP-1 Agonists for Weight Loss: Pharmacology and Clinical Implications","volume":"40","author":"Moore","year":"2023","journal-title":"Adv Ther."},{"issue":"5","key":"10.1016\/j.gene.2024.148500_b0245","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jbiosc.2015.03.003","article-title":"Signal peptide optimization tool for the secretion of recombinant protein from Saccharomyces cerevisiae","volume":"120","author":"Mori","year":"2015","journal-title":"J Biosci Bioeng."},{"issue":"5","key":"10.1016\/j.gene.2024.148500_b0250","doi-asserted-by":"crossref","first-page":"285","DOI":"10.7883\/yoken.JJID.2006.285","article-title":"Biodistribution of a low dose of intravenously administered AAV-2, 10, and 11 vectors to cynomolgus monkeys","volume":"59","author":"Mori","year":"2006","journal-title":"Jpn J Infect Dis."},{"key":"10.1016\/j.gene.2024.148500_b0255","article-title":"Adeno-associated viruses for gene therapy - clinical implications and liver related complications, a guide for hepatologists","author":"M\u00fccke","year":"2023","journal-title":"J Hepatol."},{"key":"10.1016\/j.gene.2024.148500_b0260","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol Metab."},{"issue":"3","key":"10.1016\/j.gene.2024.148500_b0265","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1093\/nar\/gkv019","article-title":"A minimal ubiquitous chromatin opening element (UCOE) effectively prevents silencing of juxtaposed heterologous promoters by epigenetic remodeling in multipotent and pluripotent stem cells","volume":"43","author":"M\u00fcller-Kuller","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.gene.2024.148500_b0270","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.reth.2020.01.004","article-title":"Advances in regenerative therapy: A review of the literature and future directions","volume":"14","author":"Ntege","year":"2020","journal-title":"Regen Ther."},{"key":"10.1016\/j.gene.2024.148500_b0275","article-title":"Mammalian cell culture for production of recombinant proteins: A review of the critical steps in their biomanufacturing","volume":"43","author":"O'Flaherty","year":"2020","journal-title":"Biotechnol Adv."},{"issue":"11","key":"10.1016\/j.gene.2024.148500_b0280","doi-asserted-by":"crossref","first-page":"e13253","DOI":"10.1111\/acel.13253","article-title":"Proteomic assessment of serum biomarkers of longevity in older men","volume":"19","author":"Orwoll","year":"2020","journal-title":"Aging Cell."},{"issue":"16","key":"10.1016\/j.gene.2024.148500_b0285","doi-asserted-by":"crossref","first-page":"7875","DOI":"10.1128\/JVI.00649-08","article-title":"Adeno-associated virus vector genomes persist as episomal chromatin in primate muscle","volume":"82","author":"Penaud-Budloo","year":"2008","journal-title":"J Virol."},{"key":"10.1016\/j.gene.2024.148500_b0290","article-title":"SPSED: A Signal Peptide Secretion Efficiency Database","volume":"9","author":"Peng","year":"2021","journal-title":"Front Bioeng Biotechnol."},{"issue":"Suppl 4","key":"10.1016\/j.gene.2024.148500_b0295","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/hae.14545","article-title":"Gene therapy: Practical aspects of implementation","volume":"28","author":"Pipe","year":"2022","journal-title":"Haemophilia."},{"key":"10.1016\/j.gene.2024.148500_b0300","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212283","article-title":"A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond","volume":"4","author":"Prasad-Reddy","year":"2015","journal-title":"Drugs Context."},{"issue":"12","key":"10.1016\/j.gene.2024.148500_b0305","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1016\/j.ymthe.2022.09.015","article-title":"AAV vectors: The Rubik's cube of human gene therapy","volume":"30","author":"Pupo","year":"2022","journal-title":"Mol Ther."},{"issue":"11","key":"10.1016\/j.gene.2024.148500_b0310","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ejmg.2018.04.010","article-title":"Improved molecular platform for the gene therapy of rare diseases by liver protein secretion","volume":"61","author":"Quiviger","year":"2018","journal-title":"Eur J Med Genet."},{"issue":"15","key":"10.1016\/j.gene.2024.148500_b0315","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1016\/j.cell.2022.03.045","article-title":"Therapeutic in vivo delivery of gene editing agents","volume":"185","author":"Raguram","year":"2022","journal-title":"Cell."},{"key":"10.1016\/j.gene.2024.148500_b0320","article-title":"Non viral vectors in gene therapy- an overview","author":"Ramamoorth","year":"20159101","journal-title":"J Clin Diagn Res"},{"issue":"6","key":"10.1016\/j.gene.2024.148500_b0325","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/btpr.2706","article-title":"Cell culture media for recombinant protein expression in Chinese hamster ovary (CHO) cells: History, key components, and optimization strategies","volume":"34","author":"Ritacco","year":"2018","journal-title":"Biotechnol Prog."},{"issue":"12","key":"10.1016\/j.gene.2024.148500_b0330","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.2337\/dbi20-0036","article-title":"Viral and Nonviral Transfer of Genetic Materials to Adipose Tissues: Toward a Gold Standard Approach","volume":"69","author":"Romanelli","year":"2020","journal-title":"Diabetes."},{"issue":"3","key":"10.1016\/j.gene.2024.148500_b0335","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.21873\/anticanres.14062","article-title":"Systematic Review on Infusion Reactions to and Infusion Rate of Monoclonal Antibodies Used in Cancer Treatment","volume":"40","author":"Rombouts","year":"2020","journal-title":"Anticancer Res."},{"key":"10.1016\/j.gene.2024.148500_b0340","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev-med-043021-033013","article-title":"Adeno-Associated Virus Gene Therapy for Hemophilia","volume":"74","author":"Samelson-Jones","year":"2023","journal-title":"Annu Rev Med."},{"issue":"1\u20132","key":"10.1016\/j.gene.2024.148500_b0345","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.cellimm.2005.01.010","article-title":"The critical DNA flanking sequences of a CpG oligodeoxynucleotide, but not the 6 base CpG motif, can be replaced with RNA without quantitative or qualitative changes in Toll-like receptor 9-mediated activity","volume":"232","author":"Sen","year":"2004","journal-title":"Cell Immunol."},{"key":"10.1016\/j.gene.2024.148500_b0350","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.biopha.2018.08.088","article-title":"Recent updates on GLP-1 agonists: Current advancements & challenges","volume":"108","author":"Sharma","year":"2018","journal-title":"Biomed Pharmacother."},{"issue":"3","key":"10.1016\/j.gene.2024.148500_b0355","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","article-title":"Immune Responses to Viral Gene Therapy Vectors","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol Ther."},{"issue":"2","key":"10.1016\/j.gene.2024.148500_b0360","doi-asserted-by":"crossref","first-page":"237","DOI":"10.5114\/aoms.2020.93253","article-title":"2020 Guidelines of the Polish Society of Laboratory Diagnostics (PSLD) and the Polish Lipid Association (PoLA) on laboratory diagnostics of lipid metabolism disorders","volume":"16","author":"Solnica","year":"2020","journal-title":"Arch Med Sci."},{"issue":"5","key":"10.1016\/j.gene.2024.148500_b0365","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.ymthe.2018.03.001","article-title":"A Rapamycin-Activated Caspase 9-Based Suicide Gene","volume":"26","author":"Stavrou","year":"2018","journal-title":"Mol Ther."},{"issue":"1","key":"10.1016\/j.gene.2024.148500_b0370","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s13311-018-00694-0","article-title":"Gene Therapy for Neurodegenerative Diseases","volume":"16","author":"Sudhakar","year":"2019","journal-title":"Neurotherapeutics."},{"issue":"1\u20132","key":"10.1016\/j.gene.2024.148500_b0375","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11010-020-03834-3","article-title":"Gene therapy: a double-edged sword with great powers","volume":"474","author":"Tang","year":"2020","journal-title":"Mol Cell Biochem."},{"key":"10.1016\/j.gene.2024.148500_b0380","series-title":"Gene Therapy","first-page":"Ch. 3","article-title":"Silencing of Transgene Expression: A Gene Therapy Perspective","author":"Tolmachov","year":"2013"},{"issue":"2","key":"10.1016\/j.gene.2024.148500_b0385","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2337\/dc10-1677","article-title":"Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans","volume":"34","author":"van Raalte","year":"2011","journal-title":"Diabetes Care."},{"key":"10.1016\/j.gene.2024.148500_b0390","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jconrel.2018.08.001","article-title":"Subcutaneous delivery of monoclonal antibodies: How do we get there?","volume":"286","author":"Viola","year":"2018","journal-title":"J Control Release."},{"issue":"2","key":"10.1016\/j.gene.2024.148500_b0395","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3390\/jfb6020379","article-title":"Lipid Nanoparticles for Ocular Gene Delivery","volume":"6","author":"Wang","year":"2015","journal-title":"J Funct Biomater."},{"issue":"1","key":"10.1016\/j.gene.2024.148500_b0400","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1186\/s12967-023-04484-x","article-title":"Cell-therapy for Parkinson's disease: a systematic review and meta-analysis","volume":"21","author":"Wang","year":"2023","journal-title":"J Transl Med."},{"issue":"13","key":"10.1016\/j.gene.2024.148500_b0405","doi-asserted-by":"crossref","first-page":"6753","DOI":"10.1093\/nar\/gkz483","article-title":"Identification of DNA motifs that regulate DNA methylation","volume":"47","author":"Wang","year":"2019","journal-title":"Nucleic Acids Res."},{"issue":"6","key":"10.1016\/j.gene.2024.148500_b0410","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s13318-022-00796-3","article-title":"Development and Validation of a Length- and Habitus-Based Method of Ideal and Lean Body Weight Estimation for Adults Requiring Urgent Weight-Based Medical Intervention","volume":"47","author":"Wells","year":"2022","journal-title":"Eur J Drug Metab Pharmacokinet."},{"key":"10.1016\/j.gene.2024.148500_b0415","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1136\/bmj.p2706","article-title":"UK regulator approves \u201cgroundbreaking\u201d gene treatment for sickle cell and beta thalassaemia","volume":"383","author":"Wilkinson","year":"2023","journal-title":"BMJ."},{"issue":"4","key":"10.1016\/j.gene.2024.148500_b0420","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s00253-022-12342-x","article-title":"Progress in fed-batch culture for recombinant protein production in CHO cells","volume":"107","author":"Xu","year":"2023","journal-title":"Appl Microbiol Biotechnol."},{"key":"10.1016\/j.gene.2024.148500_b0425","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.addr.2018.07.009","article-title":"Battle of GLP-1 delivery technologies","volume":"130","author":"Yu","year":"2018","journal-title":"Adv Drug Deliv Rev."},{"issue":"1","key":"10.1016\/j.gene.2024.148500_b0430","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1021\/acs.molpharmaceut.2c00555","article-title":"First-in-Patient Dose Prediction for Adeno-Associated Virus-Mediated Hemophilia Gene Therapy Using Allometric Scaling","volume":"20","author":"Zou","year":"2023","journal-title":"Mol Pharm."}],"container-title":["Gene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111924003810?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111924003810?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:50:11Z","timestamp":1762303811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378111924003810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":86,"alternative-id":["S0378111924003810"],"URL":"https:\/\/doi.org\/10.1016\/j.gene.2024.148500","relation":{},"ISSN":["0378-1119"],"issn-type":[{"type":"print","value":"0378-1119"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and characterization of a first-in-class adjustable-dose gene therapy system","name":"articletitle","label":"Article Title"},{"value":"Gene","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gene.2024.148500","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"148500"}}